New total-body PET scanner test in people with NSCLC, head and neck cancer, and prostate cancer

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is an observational quality-improvement protocol to explore the capabilities of the Biograph Vision Quadra total-body PET/CT system. The study includes patients with non-small cell lung cancer, head and neck cancer, and prostate cancer. Participants may undergo imaging at the Memorial Sloan Kettering campuses, with inclusion criteria spanning various disease sites and ongoing scans. The goal is to determine image quality and pharmacokinetic visualization when imaging all disease sites simultaneously. The study does not specify a intervention beyond the use of the new scanner for imaging.

Why it matters

Who can join: the full rules

Inclusion Criteria:

Eligibility Criteria for objective #1:

* Patients with histologically-confirmed non-small cell lung carcinoma (NSCLC) with a single or multiple lung nodules.
* Patients who are undergoing a planned PET-CT scan at main campus of MSK.
* Patients must be ≥ 18 years old

Eligibility Criteria for objective #2:

* Patients with disease within the chest, abdomen or pelvis, who could benefit from visualizing the pharmacokinetics of radiotracer uptake within all disease sites simultaneously.
* Patients with metastatic prostate or head and neck cancer.
* Patients with prostate cancer who are undergoing a 68Ga-PSMA or 18F-FDG scan at the main campus of MSK.
* Patients with head and neck cancer who are undergoing a 18F-FDG scan at the main campus of MSK
* Patients must be ≥ 18 years old

Eligibility Criteria for objective #3:

* Patients with histologically-confirmed cancer from all three groups (lung cancer, head and neck cancer, prostate cancer).
* Patients who are undergoing an 68Ga-PSMA or 18F-FDG or an \[18F\]-fluormisonidazole PET-CT scan at the main campus of MSK.
* Patients willing to return to the MITS clinc for late imaging session between 2 to 6 hours after the PET radiotracer injection. (In current practice, FDG is imaged between 1 and 1.5 hours post injection, and FMISO is imaged between 2.5 and 3 hours post injection)
* Patients must be ≥ 18 years old

Eligibility Criteria for objective #4:

* Patients who are undergoing a planned PET-CT scan at main campus of MSK with a radiotracer
* Patients must be ≥ 18 years old

Exclusion Criteria:

* Patients who suffer from claustrophobia.
* Women who are pregnant or breast-feeding.
* Patients \< 18 years of age

Where it's running

• Memorial Sloan Kettering Basking Ridge (Consent Only)
  Basking Ridge, New Jersey, United States Recruiting
• Memorial Sloan Kettering Monmouth (Consent Only)
  Middletown, New Jersey, United States Recruiting
• Memorial Sloan Kettering Bergen (Consent Only )
  Montvale, New Jersey, United States Recruiting
• Memorial Sloan Kettering Suffolk-Commack (Consent Only)
  Commack, New York, United States Recruiting
• Memorial Sloan Kettering Westchester (Consent Only)
  Harrison, New York, United States Recruiting
• Memorial Sloan Kettering Cancer Center
  New York, New York, United States Recruiting

Study contacts

• Principal investigator: Heiko Schoder, MD — Memorial Sloan Kettering Cancer Center
• Study coordinator: Heiko Schoder, MD
• Email: schoderh@mskcc.org
• Phone: 212-639-8001

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Docetaxel and SX-682 in head and neck cancers and prostate cancer

  This trial tests a new drug SX-682 together with docetaxel in adults whose head and neck cancers or prostate cancer have returned or spread.

  Recruiting Phase 1/2 National Institutes of Health Clinical Center (CC) · Bethesda, Maryland · NCT07667400

• OCT-598 for advanced solid tumors

  This trial tests whether OCT-598, by itself or with docetaxel, is safe and to find the best dose for adults with advanced solid tumors who have limited standard treatment options.

  Recruiting at 2 sites Phase 1 Oscotec Inc. · Goyang-si and 2 other locations · NCT07358806

• Collecting blood and leftover tumor tissue to test molecular residual disease (MRD) detection

  This project will test whether blood and leftover tumor tissue from adults with certain solid tumors can be used with Natera's MRD blood tests to find tiny amounts of cancer (ctDNA) after treatment.

  Recruiting Natera, Inc. · Austin, Texas · NCT07318051

• Testing trastuzumab deruxtecan (T‑DxD) for HER2‑positive advanced solid tumors

  This will test whether trastuzumab deruxtecan (T‑DxD) helps adults in the US with HER2‑positive (IHC 3+) locally advanced, unresectable, or metastatic solid tumors who have had prior systemic treatment and have no satisfactory alternative options.

  Recruiting at 18 sites AstraZeneca · Birmingham, Alabama and 17 other locations · NCT07124000

• Virtual exercise program to preserve function and prevent disability during chemotherapy

  This trial tests whether supervised resistance sessions by video plus short home aerobic workouts help adults 18–64 maintain strength and stay active while receiving curative-intent chemotherapy.

  Recruiting at 29 sites Alliance for Clinical Trials in Oncology · Dublin, California and 29 other locations · NCT07059884

• ImmunoPET imaging for solid tumors targeting Trop2

  This study is testing a new imaging method to see if it can help diagnose solid tumors like bladder and prostate cancer better than current methods.

  Recruiting Phase 2/3 RenJi Hospital · Shanghai · NCT06851663

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.